Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9326011 | 1.00 | — | — | |
| SCHEMBL33803 | 0.95 | — | — | |
| Bromide SCHEMBL9325451 | 0.91 | — | — | |
| SCHEMBL8346547 | 0.91 | — | — | |
| Ammonia Solution, Strong SCHEMBL15865146 | 0.91 | — | — | |
| SCHEMBL29600487 | 0.91 | — | — | |
| Iodide SCHEMBL9744545 | 0.87 | — | — | |
| Trimethylammonium SCHEMBL28228946 | 0.86 | TSHR (0.42) | — | |
| SCHEMBL10491530 | 0.84 | TP53 (0.46) | — | |
| Propane SCHEMBL11669914 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831394-B1 | CROSS-LINKED CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND TREATMENT AGENT FOR EYE DISEASE | SEIKAGAKU KOGYO CO LTD (JP) | 2022-12-21 | — | — | EP | disclosed |
| US-11207345-B2 | Crosslinked chondroitin sulfate, composition containing same, and treatment agent for eye disease | SEIKAGAKU CORPORATION (JP) | 2021-12-28 | — | — | US | disclosed |
| EP-3831394-A1 | CROSS-LINKED CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND TREATMENT AGENT FOR EYE DISEASE | Seikagaku Corporation (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-20210052634-A1 | CROSSLINKED CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND TREATMENT AGENT FOR EYE DISEASE | SEIKAGAKU CORPORATION (JP) | 2021-02-25 | — | — | US | disclosed |
| US-10716804-B2 | Crosslinked chondroitin sulfate, composition containing same, and treatment agent for eye disease | SEIKAGAKU CORPORATION (JP) | 2020-07-21 | — | — | US | disclosed |
| US-10420796-B2 | Crosslinked chondroitin sulfate, composition containing same, and treatment agent for eye disease | SEIKAGAKU CORPORATION (JP) | 2019-09-24 | — | — | US | disclosed |
| US-20170368093-A1 | CROSSLINKED CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND TREATMENT AGENT FOR EYE DISEASE | SEIKAGAKU CORPORATION (JP) | 2017-12-28 | — | — | US | disclosed |
| EP-3246037-A1 | CROSSLINKED CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND TREATMENT AGENT FOR EYE DISEASE | Seikagaku Corporation (JP) | 2017-11-22 | — | — | EP | disclosed |
| EP-2536283-B1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA LLC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-9045461-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140206660-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-8741900-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130197007-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8431575-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2536283-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TransTech Pharma, Inc (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-0320796-B1 | Process for the preparation of phosphoric-acid derivatives and intermediates | BAYER AG (DE) | 1994-03-09 | — | — | EP | disclosed |
| US-5010193-A | Cyclization, oxidation, dehydrogenation, salt formation, desalting, phosphorylating; insecticides | BAYER AKTIENGESELLSCHAFT (DE) | 1991-04-23 | — | — | US | disclosed |
| EP-0320796-A2 | Process for the preparation of phosphoric-acid derivatives and intermediates | BAYER AG (DE) | 1989-06-21 | — | — | EP | disclosed |
| US-4311709-A | Loweralkyl substituted diphenyl polyamine as an antimicrobial agent | MERCK & CO., INC. (US) | 1982-01-19 | — | — | US | disclosed |
| EP-0032031-A2 | Use of polyamine compounds in prevention of mastitis | MERCK & CO. INC. (US) | 1981-07-15 | — | — | EP | disclosed |